A Parent’s Testimonial
Shared Decision-making in Pediatric Asthma
Patel SJ, Teach SJ. Pediatr Rev. 2019;40(11):549-567.
Bush A. J Clin Med. 2020;9(4):1237.
Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program.
Fitzpatrick AM, et al. J Allergy Clin Immunol. 2011;127(2):382-389.
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Lanier B, et al. J Allergy Clin Immunol. 2009;124(6):1210-1216.
Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A, et al. J Allergy Clin Immunol. 2019;144(5):1336-1342.e7.
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM, et al. Lancet Respir Med. 2018;6(1):51-64.
Castro M, et al. N Engl J Med. 2018;378(26):2486-2496.
Dupilumab efficacy and safety in children with uncontrolled, moderate-to-severe asthma: the phase 3 VOYAGE study.
Bacharier LB, et al. ATS 2021. Abstract A1204.
Efficacy and safety of tezepelumab in adults and adolocesents with severe, uncontrolled asthma: results the phase 3 NAVIGATOR study.
Menzies-Gow A, et al J Allergy Clin Immunol.2021;147(2):AB249.
A Breath of Fresh Air in Pediatric Asthma
Shared Decision-making in the Era of Biologics
|Faculty:||Mario Castro, MD, MPH; Wanda Phipatanakul, MD, MS|